83949-38-6

Basic information

• Product Name: 4-methoxy-4-phenylpiperidinium chloride
• Synonyms: 4-methoxy-4-phenylpiperidinium chloride;4-methoxy-4-phenylpiperidine hydrochloride
• CAS NO: 83949-38-6
• Molecular Formula: C₁₂H₁₇NO*ClH
• Molecular Weight: 227.73042
• EINECS: 281-398-5
• Mol File: 83949-38-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 284°C at 760 mmHg
• Flash Point: 115.1°C
• Appearance: /
• Vapor Pressure: 0.00307mmHg at 25°C
• CAS DataBase Reference: 4-methoxy-4-phenylpiperidinium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-4-phenylpiperidinium chloride(83949-38-6)
• EPA Substance Registry System: 4-methoxy-4-phenylpiperidinium chloride(83949-38-6)

Safety Data

• Hazardous Substances Data: 83949-38-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H17NO.ClH/c1-14-12(7-9-13-10-8-12)11-5-3-2-4-6-11;/h2-6,13H,7-10H2,1H3;1H/p-1

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 591-51-5 phenyllithium 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 
• 201609-37-2 4-methoxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1254980-09-0 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine 

Relevant articles and documents

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.